SCYX has been consolidating into this bullish wedge for months now. With upcoming catalysts, such as the first FDA approval for their ibrexafungerp antifungal in Q1 2021 and other catalyst announcements potentially in Q4 2020, this looks prime for a large break out over $10.
I will be buying at any price within this wedge with a target >$20 for profit taking.